# 61Cu-NODAGA-LM3 PET/CT for the Detection of Neuroendocrine Tumors (COPPER PET in NET)

> **NCT06455358** · PHASE1,PHASE2 · RECRUITING · sponsor: **University Hospital, Basel, Switzerland** · enrollment: 27 (estimated)

## Conditions studied

- Neuroendocrine Tumors

## Interventions

- **DRUG:** 61Cu-NODAGA-LM3
- **OTHER:** Comparator

## Key facts

- **NCT ID:** NCT06455358
- **Lead sponsor:** University Hospital, Basel, Switzerland
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-05
- **Primary completion:** 2028-06
- **Final completion:** 2028-06
- **Target enrollment:** 27 (ESTIMATED)
- **Last updated:** 2025-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06455358

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06455358, "61Cu-NODAGA-LM3 PET/CT for the Detection of Neuroendocrine Tumors (COPPER PET in NET)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06455358. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*